Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy
Authors' conclusion
In patients with partial lipodystrophy, tirzepatide use resulted in substantial statistically significant reductions in weight, glycemic control, serum triglycerides, and daily insulin requirement.
Study context
- Population
- Patients with partial lipodystrophy (PLD) treated with tirzepatide, January 2022–September 2025; FPLD1 like 65%, FPLD2 10%, FPLD3 17.5%, FPLD7 2.5%, APLD 2.5%, unclassified 2.5%; 87.5% female, median age 47 years (IQR 39–59), median BMI 31.5 kg/m² (IQR 27.3 to 35.5)single group
- Participants
- 40 patients
- Exposure
- Before vs after tirzepatide treatment
- Tirzepatiden = 40
- Outcome
- Change from baseline in body weight, HbA1c, serum TG and daily insulin requirement
- Follow-up
- Median 9.5 month (IQR 7 to 11)
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Body weight, baseline → follow-up (median, IQR)
91.0 kg (IQR 75.0 to 106.0) to 82.8 kg (IQR 69.0 to 93.4)
P < .0001
HbA1c, baseline → follow-up (median, IQR)
65 mmol/mol (IQR 54.5 to 85) to 52 mmol/mol (IQR 39 to 62)
P < .0001
Serum TG, baseline → follow-up (median, IQR)
2.80 mmol/L (IQR 1.6 to 3.7) to 1.83 mmol/L (IQR 1.0 to 2.9)
P = .0005
Daily insulin requirement, baseline → follow-up (median, IQR)
177.5 IU (IQR 101.3 to 213.8) to 58.0 IU (IQR 0 to 112.5)
P = .0028
Observational data: associations, not effects.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →